TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2508049
Drug: piperacillin, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin, 300 mg/kg/day plus tobramycin, 10 and more mg/kg/day for 14 days
Study: 2508049
Drug: ceftazidime, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftazidime, 150 mg/kg/day for 14 days
Study: 25589624
Drug: Cyclophosphamide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide + Veliparib (60 mg orally once daily)
Study: 25589624
Drug: Cyclophosphamide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide alone (50 mg orally once daily)
Study: 23936331
Drug: Urinary betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary betaine excretion in patients with diabetes mellitus (n = 264)
Study: 23936331
Drug: Urinary betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary betaine excretion
Study: 23936331
Drug: Baseline betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline betaine excretion
Study: 21882087
Drug: Low-contrast dose
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-contrast dose protocol (P(low)): iohexol-350 [0.7 ml/kg body weight (BW)] during 9 s
Study: 21882087
Drug: Conventional protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protocol (P(conv)): iohexol-350 (1.0 ml/kg BW) during 15 s
Study: 15193740
Drug: Gliclazide 80
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80 mg (formulation 1)
Study: 15193740
Drug: Gliclazide 80
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80 mg (formulation 2)
Study: 11331167
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg rofecoxib capsule po 1 hour before induction of anesthesia
Study: 11331167
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule po 1 hour before induction of anesthesia
Study: 9154397
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine 1% solution
Study: 7700076
Drug: cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 2.5 mg once daily
Study: 7700076
Drug: cilazapril 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 5.0 mg once daily
Study: 27001782
Drug: Vibrating massage
Normalized name: VIBRATING DEVICE,CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrating massage of all masseter muscles, tourmaline ceramic on the joint area, and local physical therapy.
Study: 23437055
Drug: MYM-V101 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYM-V101 vaccine at 10 μg/dose
Study: 23437055
Drug: MYM-V101 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYM-V101 vaccine at 50 μg/dose
Study: 23437055
Drug: MYM-V101 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYM-V101 vaccine (both doses)
Study: 23437055
Drug: MYM-V101 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYM-V101 vaccine (high dose)
Study: 18834276
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for complicated grief
Study: 12953347
Drug: CHF 3381
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 3381 (25, 50, 100, 200, 300, 450, and 600 mg)
Study: 12953347
Drug: CHF 3381
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 3381 (600 mg)
Study: 12953347
Drug: CHF 3381
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 3381 (various doses)
Study: 12953347
Drug: CHF 3381
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 3381 (300 and 600 mg)
Study: 12953347
Drug: CHF 3381
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 3381 (200 mg)
Study: 12953347
Drug: CHF 3381
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 3381 (300 mg)
Study: 10962546
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (20 mg daily subcutaneous injection)
Study: 8722342
Drug: Busulfan 16
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (BuCy2) preparative regimen
Study: 3901832
Drug: 12-hour theophylline
Normalized name: 12 HR theophylline 350 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour theophylline preparation (Theo-Dur)
Study: 3901832
Drug: 24-hour theophylline
Normalized name: 24 HR theophylline 150 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour theophylline preparation (Theo-24)
Study: 29381569
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion therapy (3 mg/kg) administered once a week for 4 consecutive weeks
Study: 29381569
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusions (control group) administered once a week for 4 consecutive weeks
Study: 25699349
Drug: Voluven 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluven 7 ml/kg in 20 mins before induction and 8 ml/kg after induction
Study: 25699349
Drug: Plasmalyte A
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalyte A 6 ml/kg/h
Study: 22856218
Drug: Hyperbaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 10% glucose)
Study: 22856218
Drug: Hypobaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric solution (7.5 mg levobupivacaine + 50 microg Fentanyl + 1 ml 0.9% NaCl)
Study: 3277875
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal suppositories
Study: 18019402
Drug: Valacyclovir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir at 14.3 mg/kg every 6 hours
Study: 16615261
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (intervention group)
Study: 16615261
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prior to insulin infusion)
Study: 14669937
Drug: 7.75% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.75% carbohydrate solution
Study: 14669937
Drug: 7.75% carbohydrate/1.94%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.75% carbohydrate/1.94% protein solution
Study: 10947748
Drug: Rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1.5 mg x kg(‐1) with neostigmine
Study: 10947748
Drug: Rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1.5 mg x kg(‐1) without neostigmine
Study: 10947748
Drug: Succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0 mg x kg(‐1)
Study: 10947748
Drug: Rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1.5 mg x kg(‐1)
Study: 8773908
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as no treatment or different duration)
Study: 8773908
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with interferon
Study: 1537998
Drug: Accelerated rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated rt‐PA (1.25 mg/kg over 90 min, regimen C)
Study: 1537998
Drug: Exaggerated (60‐min)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exaggerated (60‐min) dosage regimen
Study: 1537998
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (accelerated rt‐PA and intravenous urokinase, regimen E)
Study: 1537998
Drug: Conventional 3‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 3‐h dosing regimens
Study: 29061222
Drug: Improvisational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisational music therapy (IMT) - high-frequency sessions (3 sessions per week)
Study: 29061222
Drug: Improvisational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisational music therapy (IMT) - low-frequency sessions (1 session per week)
Study: 29061222
Drug: Improvisational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisational music therapy (IMT)
Study: 25822648
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow MSCs (40 × 10^6 cells, intra-articular injection)
Study: 25822648
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (60 mg, single dose, intra-articular)
Study: 15288592
Drug: pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40 mg/day plus piperazine-sultosilate 1000 mg/day
Study: 25148829
Drug: pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40 mg/day
Study: 8202005
Drug: Single-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose prednisolone
Study: 3479045
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g) administered at 12-hour intervals
Study: 3479045
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 12-hour intervals
Study: 22647321
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation treatment (MRT)
Study: 26581842
Drug: Atorvastatin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (oral 20 mg/night for 8 weeks)
Study: 23738908
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of EMLA cream (5% lidocaine 25 mg‐prilocaine 25 mg/g)
Study: 23738908
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of ultrasound gel (placebo)
Study: 20684147
Drug: Two-compound ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g)
Study: 20684147
Drug: Two-compound ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound ointment (calcipotriene 50 microg/g and betamethasone 0.5 mg/g) for 52 weeks
Study: 20684147
Drug: Two-compound ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound ointment alternating with calcipotriene four-weekly
Study: 20684147
Drug: Betamethasone 0.5
Normalized name: betamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.5 mg/g (as dipropionate; Diprosone) ointment
Study: 12923616
Drug: Sufentanil (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (initial bolus 0.5 micro g/kg and continuous infusion rate of 0.5 micro g/kg per hour)
Study: 12923616
Drug: Midazolam (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (initial bolus 0.08 mg/kg and continuous infusion 0.05 mg/kg per hour)
Study: 10875787
Drug: Oral BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BCG vaccination (double-dose)
Study: 10875787
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG booster vaccination
Study: 10875787
Drug: Oral BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BCG vaccination
Study: 28384828
Drug: Hydrocortisone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days)
Study: 25117853
Drug: Vigabatrin 1
Normalized name: vigabatrin 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 1 g/day
Study: 25117853
Drug: Vigabatrin 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 6 g/day
Study: 23835026
Drug: Intra-arterial thrombolysis
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombolysis (IAT) after intravenous thrombolysis (IVT)
Study: 21993064
Drug: Chlorhexidine mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthrinse (10 ml of 0.2%)
Study: 21993064
Drug: Cacao bean
Normalized name: Cacao bean
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cacao bean husk extract mouthrinse (10 ml of 0.1%)
Study: 18785254
Drug: Atrasentan 10
Normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 10 mg daily
Study: 16541325
Drug: Cyclophosphamide, methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, methotrexate, fluoracil (CMF) chemotherapy
Study: 12925248
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice a day for 72 hours
Study: 12925248
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 to 80 mg intravenously during surgery)
Study: 6150902
Drug: prenalterol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: prenalterol (1 mg/60 min)
Study: 6150902
Drug: prenalterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: prenalterol (2 mg/60 min)
Study: 27842163
Drug: Anti-VEGF therapy
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF therapy (Bevacizumab and Ranibizumab) administered monthly for 6 months
Study: 16645969
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg/day
Study: 12160813
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL lignocaine 2% with sodium hyaluronidase 150 IU/mL
Study: 12160813
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL plain lignocaine 2%
Study: 29693796
Drug: Cabozantinib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 30 mg/m2/day
Study: 29693796
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg/m2/day
Study: 29693796
Drug: Cabozantinib 55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 55 mg/m2/day
Study: 29693796
Drug: Cabozantinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (all dose levels)
Study: 26916566
Drug: Siponimod 4
Normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Siponimod 4 mg after 192 hours of discontinuation
Study: 26916566
Drug: Siponimod (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod (various doses) after up to 96 hours of discontinuation
Study: 26916566
Drug: Siponimod (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod (various doses)
Study: 25594427
Drug: CT327 (TrkA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT327 (TrkA inhibitor)
Study: 23099100
Drug: Computerized decision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized decision support tools in the EHR with direct-to-parent support (telephone coaching and twice-weekly text messages)
Study: 8677865
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (n = 911; 33%)
Study: 8677865
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker therapy (n = 1,812; 67%)
Study: 1355798
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine (5 x 10(6), 5 x 10(7), 5 x 10(8), 5 x 10(9), or 1 x 10(10) CFU)
Study: 1355798
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine (5 x 10(8) CFU)
Study: 1355798
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine (5 x 10(9) CFU)
Study: 29742655
Drug: Gabapentin (1,200-3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,200-3,000 mg/d)
Study: 24152706
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) loading (5 g of Cr + 10 g of fructose, four times daily for 5 days)
Study: 24152706
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g of fructose, four times daily for 5 days)
Study: 23155026
Drug: Heavier hens
Normalized name: Bartonella henselae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavier hens (1,733 g)
Study: 23155026
Drug: Lighter hens
Normalized name: Bartonella henselae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lighter hens (1,606 g)
Study: 20538329
Drug: Diluent inhalation
Normalized name: DILUENT
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluent inhalation
Study: 16259830
Drug: Current users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current users of hormone replacement therapy (HRT)
Study: 16259830
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of hormone replacement therapy (HRT)
Study: 8681495
Drug: Albendazole (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (440 mg/two times per day for 7 days)
Study: 8681495
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/two times per day for 7 days) plus metronidazole (250 mg/three times per day for 7 days)
Study: 30982748
Drug: Hydrogen-rich water
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich water (HRW) 1 L per day for 28 days
Study: 21878535
Drug: Letrozole +
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole + AS1402 (9 mg/kg weekly infusion)
Study: 21878535
Drug: Letrozole only
Normalized name: Letrozole only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole only (2.5 mg daily)
Study: 17950094
Drug: Miglitol 150
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 150 mg/d
Study: 17950094
Drug: Mitiglinide 30
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 30 mg/d
Study: 11332926
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg elemental)
Study: 9110923
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg once daily)
Study: 9110923
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate (200 mg once daily)
Study: 28202033
Drug: Stepwise lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise lactate kinetics-oriented hemodynamic therapy
Study: 28202033
Drug: ScvO2-oriented hemodynamic
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ScvO2-oriented hemodynamic therapy
Study: 26387028
Drug: Loading-dose rosuvastatin
Normalized name: omadacycline 7-Day Oral Pack incuding loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading-dose rosuvastatin 20 mg 12 hours prior to PCI, with a second dose just before PCI.
Study: 26387028
Drug: Loading-dose rosuvastatin
Normalized name: omadacycline 7-Day Oral Pack incuding loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading-dose rosuvastatin therapy.
Study: 23288870
Drug: Simvastatin/ezetimibe 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/ezetimibe 10/10 mg
Study: 21627526
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B (2 mL doses, n = 12)
Study: 21627526
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A (5 mL doses, n = 13)
Study: 21627526
Drug: Sham vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham vaccine (n = 14)
Study: 17225048
Drug: Groups A,
Normalized name: Meningococcal Polysaccharide Vaccine, Groups A, C Combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups A, B, C (iodine dose 450-600 mg/kg, injection duration 30 s)
Study: 17225048
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (iodine dose 450 mg/kg, injection duration 25 s)
Study: 15321810
Drug: High-soy diet
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-soy diet (104 +/- 24 mg total isoflavones/d)
Study: 15321810
Drug: Low-soy diet
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-soy diet (0.54 +/- 0.58 mg total isoflavones/d)
Study: 3364822
Drug: Epinephrine 1
Normalized name: epinephrine 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 1 mg
Study: 9512230
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) in patients with previous failed fertilization or low fertilization rate
Study: 9512230
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) in patients with primary male factor
Study: 7518728
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment for 4 months in males